On January 28, the Susan G. Komen Foundation released an episode of their podcast “Real Pink” entitled “The Evolution of Biosimilars as a Cancer Treatment” featuring Andrew Spiegel. Mr. Spiegel is Executive Director of the Global Colon Cancer Association and a founding member of ASBM.
In the podcast, Spiegel explains how biologic medicines have extended the life expectancy of cancer patients, and how biosimilars can bring these patients new treatment options at reduced cost.
He also details concerns among the physician and patient community surrounding “non-medical switching“- forced switching by third parties such as insurance companies, for financial reasons rather than the health of the patient.
Download/Listen to the podcast here.
Learn more about non-medical switching here.